Article Details

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi ...

Retrieved on: 2021-02-01 10:30:00

Tags for this article:

Click the tags to see associated articles and topics

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi .... View article details on hiswai:

Excerpt

Toripalimab is the first Chinese domestic anti-PD-1 monoclonal antibody to obtain a marketing approval in China. More than thirty company-sponsored ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up